homovanillic acid has been researched along with salicylates in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Earl, CD; Ferger, B; Kuschinsky, K; Oertel, WH; Teismann, P | 1 |
| Borah, A; Mohanakumar, KP | 1 |
2 other study(ies) available for homovanillic acid and salicylates
| Article | Year |
|---|---|
Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Count; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Free Radical Scavengers; Homovanillic Acid; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neostriatum; Neurons; Parkinson Disease, Secondary; Protective Agents; Salicylates; Substantia Nigra; Synaptic Transmission; Tyrosine 3-Monooxygenase | 1999 |
Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Levodopa; Male; Medial Forebrain Bundle; Mice; Mice, Inbred BALB C; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Salicylates | 2010 |